ICH Guidelines for Clinical Trials and Drug Development
- Home
- Publication Support
- Journal Selection
- ICH Guidelines for Clinical Trials and Drug Development
An Academy Guide
Interesting topics
ICH Guidelines for Clinical Trials and Drug Development
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) is unique in bringing together the regulatory authorities and pharmaceutical industry to discuss scientific and technical aspects of pharmaceuticals and develop ICH guidelines. Since its inception in 1990, ICH has gradually evolved to respond to increasingly global developments in the pharmaceutical sector, and these ICH guidelines are applied by a growing number of regulatory authorities. Since it announced organisational changes in October 2015, ICH has grown as an organisation and now includes 23 Members and 41 Observers. [1]
1. What are the ICH Guidelines?
ICH guidelines are an internationally accepted suite of rules and standards regarding quality, safety, and efficacy for drugs, as well as regulatory harmonisation for drug development and clinical investigation.
| Purpose: To reduce duplication in testing, to gain efficiency, and to ensure medicines are safe, effective, and are high quality, throughout their entire life cycle, worldwide | Scope: The ICH guidelines have relevance throughout the entire life cycle of a drug, including discovery and preclinical studies, clinical trials, and post-market vigilance |
2. Types of ICH Guidelines
ICH guidelines are categorized into four main types. [2]
- Quality: Includes pharmaceutical development, manufacturing, stability, impurities, and quality risk management.
- Safety: It includes toxicology, genotoxicity, reproductive toxicity, and carcinogenicity
- Efficacy: It includes clinical trial design, conduct, analysis, and reporting on studies.
- Multidisciplinary: It is the cross-cutting topics that include the Common Technical Document (CTD) and MedDRA terminology.
2.1. Quality Guidelines
These guidelines encompass various aspects of quality control throughout the drug development lifecycle. [2]
| Q1 | Stability |
| Q2 | Analytical Validation |
| Q3 | Impurities |
| Q4 | Pharmacopoeias |
| Q5 | Quality of Biotechnological Products |
| Q6 | Specifications |
| Q7 | Good Manufacturing Practice |
| Q8 | Pharmaceutical Development |
| Q9 | Quality Risk Management |
| Q10 | Pharmaceutical Quality System |
| Q11 | Development and Manufacture of Drug Substances |
| Q12 | Lifecycle Management |
| Q13 | Continuous Manufacturing of Drug Substances and Drug Products |
| Q14 | Analytical Procedure Development |
2.2. Safety Guidelines
Safety guidelines are used to identify potential hazard, e.g. carcinogenicity or genotoxicity. [2]
| S1 | Carcinogenicity Studies |
| S2 | Genotoxicity Studies |
| S3 | Toxicokinetic and Pharmacokinetics |
| S4 | Toxicity Testing |
| S5 | Reproductive Toxicology |
| S6 | Biotechnological Products |
| S7 | Pharmacology Studies |
| S8 | Immunotoxicology Studies |
| S9 | Nonclinical Evaluation for Anticancer Pharmaceuticals |
| S10 | Photo safety Evaluation |
| S11 | Nonclinical Paediatric Safety |
| S12 | Nonclinical Biodistribution Considerations for Gene Therapy Products |
| S1 | Carcinogenicity Studies |
| S2 | Genotoxicity Studies |
2.3. Efficacy Guidelines
Ensuring the efficacy of investigational products is imperative for advancing medical knowledge and improving patient outcomes. [3]
| E1 | Carcinogenicity Studies |
| E2 | Genotoxicity Studies |
| E3 | Toxicokinetic and Pharmacokinetics |
| E4 | Toxicity Testing |
| E5 | Reproductive Toxicology |
| E6 | Biotechnological Products |
| E7 | Pharmacology Studies |
| E8 | Immunotoxicology Studies |
| E9 | Nonclinical Evaluation for Anticancer Pharmaceuticals |
| E10 | Photo safety Evaluation |
| E11 | Nonclinical Paediatric Safety |
| E12 | Nonclinical Biodistribution Considerations for Gene Therapy Products |
| E14 | Clinical Evaluation of QT |
| E15 | Definitions in Pharmacogenetics / Pharmacogenomics |
2.4. Cited Half-Life:
Basically, a catch-all for anything that doesn’t fall into Quality, Efficacy, or Safety, the Multidisciplinary. [4]
| M1 | Stability |
| M2 | Analytical Validation |
| M3 | Impurities |
| M4 | Pharmacopoeias |
| M5 | Quality of Biotechnological Products |
| M6 | Specifications |
| M7 | Good Manufacturing Practice |
| M8 | Pharmaceutical Development |
| M9 | Quality Risk Management |
| M10 | Pharmaceutical Quality System |
| M11 | Development and Manufacture of Drug Substances |
| M12 | Lifecycle Management |
| M13 | Continuous Manufacturing of Drug Substances and Drug Products |
3. ICH Guidelines in Clinical Trials
ICH E6 (R2) – Good Clinical Practice: The most critical standard for clinical trials.[5]
- Ensures protection of the rights, safety, and well-being of the subjects.
- Allows for appropriate documentation, monitoring, data integrity.
- Includes informed consent and ethics review, and approval.
ICH E2A – Clinical Safety Data Management: Definitions and Standards for Expedited Reporting.
ICH E2A establishes definitions and standards for the expedited reporting of adverse drug reactions (ADRs) that occur during clinical trials.
- Defines serious adverse event (SAE) and unexpected adverse drug reactions (UADR).
- Establishes timelines and formats for expedited reporting of ADRs to regulatory authorities.
- Reduces duplication and misunderstandings caused by having different requirements for global safety reporting.
4. ICH Guideline in Drug Development
Preclinical Stage (Safety assessments; toxicity, pharmacology, ADME studies) Clinical Trials (Phase I-IV) [7]
- Phase I: First in human safety studies
- Phase II: Efficacy and as appropriate, dose-finding studies
- Phase III: Have conducted large enough studies to confirm both efficacy and safety
- Phase IV: Monitor participant health after marketing strategies
- Regulatory Submission: Apply CTD format that will expedite approvals in a harmonized way
- Post-Approval Monitoring: Continue safety reporting; as well as risk management.
Connect with us to explore how we can support you in maintaining academic integrity and enhancing the visibility of your research across the world!
Conclusion
The ICH guidelines are the foundation of modern-day clinical trials and drug development work. By providing regulatory requirements harmonization across the globe, ICH guidelines create efficiencies, while maintaining high standards of science and ethics, and ultimately, protecting patient health. They are critical to clinical researchers and those working in the drug development area for compliance, quality, and approval of drugs.
ICH Guidelines for Clinical Trials and Drug Development? Our Pubrica consultants are here to guide you.[Get Expert Publishing Support] or [Schedule a Free Consultation]
References
- Lieberman, J. (2024, April 16). An overview of ICH guidelines. Io. https://kivo.io/news/an-overview-of-ich-guidelines
- ICH Official web site : ICH. (n.d.). Ich.org. Retrieved August 16, 2025, from https://www.ich.org/page/efficacy-guidelines
- ICH Official web site : ICH. (n.d.). Ich.org. Retrieved August 16, 2025, from https://www.ich.org/page/multidisciplinary-guidelines
- Bhatt, A. (2023). The revamped Good Clinical Practice E6(R3) guideline: Profound changes in principles and practice! Perspectives in Clinical Research, 14(4), 167–171. https://doi.org/10.4103/picr.picr_184_23
- Wang, T., Jacobson-Kram, D., Pilaro, A. M., Lapadula, D., Jacobs, A., Brown, P., Lipscomb, J., & McGuinn, W. D. (2010). ICH guidelines: inception, revision, and implications for drug development. Toxicological Sciences: An Official Journal of the Society of Toxicology, 118(2), 356–367. https://doi.org/10.1093/toxsci/kfq286